Low TLR and PSMA-TV predict biochemical response to abiraterone acetate in metastatic prostate cancer patients developing castration resistance after chemohormonal therapy at hormone-sensitive stage.

MLA

Ke, Zhi-Bin, et al. “Low TLR and PSMA-TV Predict Biochemical Response to Abiraterone Acetate in Metastatic Prostate Cancer Patients Developing Castration Resistance after Chemohormonal Therapy at Hormone-Sensitive Stage.” Journal of Cancer Research and Clinical Oncology, vol. 149, no. 8, July 2023, pp. 5071–84. EBSCOhost, https://doi.org/10.1007/s00432-022-04438-8.

APA

Ke, Z.-B., Chen, J.-Y., You, Q., Sun, J.-B., Xue, Y.-T., Ye, X.-J., Chen, S.-H., Xue, X.-Y., Sun, X.-L., Chen, D.-N., Wei, Y., Zheng, Q.-S., Chen, S.-M., & Xu, N. (2023). Low TLR and PSMA-TV predict biochemical response to abiraterone acetate in metastatic prostate cancer patients developing castration resistance after chemohormonal therapy at hormone-sensitive stage. Journal of Cancer Research and Clinical Oncology, 149(8), 5071–5084. https://doi.org/10.1007/s00432-022-04438-8

Chicago

Ke, Zhi-Bin, Jia-Yin Chen, Qi You, Jiang-Bo Sun, Yu-Ting Xue, Xiao-Jian Ye, Shao-Hao Chen, et al. 2023. “Low TLR and PSMA-TV Predict Biochemical Response to Abiraterone Acetate in Metastatic Prostate Cancer Patients Developing Castration Resistance after Chemohormonal Therapy at Hormone-Sensitive Stage.” Journal of Cancer Research and Clinical Oncology 149 (8): 5071–84. doi:10.1007/s00432-022-04438-8.